What Happened? A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the ...

Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential securities law claims on behalf of shareholders. The investigation centers on whether the company and ...

The company’s net new business awards increased 39.1% to $736.6 million in the fourth quarter, resulting in a book-to-bill ratio of 1.04x. Backlog as of December 31, 2025, grew 4.3% to $3.03 billion ...

Medpace's backlog growth remains sluggish, but a healthy book-to-bill ratio and potential sector recovery could accelerate future growth. See why MEDP is a Buy.

Ratings for Medpace Hldgs (NASDAQ:MEDP) were provided by 4 analysts in the past three months, showcasing a mix of bullish and ...

Revenue for Q4 2025 was $708.5 million, up 32% year-over-year. Full year 2025 revenue was $2.53 billion, a 20% increase from 2024. EBITDA for Q4 was $160.2 million; full year EBITDA was $557.7 million ...

Giverny Capital Asset Management, LLC, an investment management company, recently published its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. The Portfolio returned 0 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Medpace’s massive expansion ...

Medpace Hldgs (NASDAQ:MEDP) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Zelluna plans to initiate the first clinical trial of ZI-MA4-1 subject to regulatory approval (CTA approval), marking a key milestone in the clinical development of the company's off-the-shelf TCR-NK ...